IL95979A - Pharmaceutical preparations containing phylomycins - Google Patents

Pharmaceutical preparations containing phylomycins

Info

Publication number: IL95979A
Authority: IL; Israel
Prior art keywords: compound; formula; treatment; bone; pharmaceutically acceptable
Prior art date: 1989-10-24

Application number

IL9597990A

Other languages

English (en)

Hebrew (he)

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-10-24

Filing date

1990-10-12

Publication date

1995-11-27

1990-10-12 Application filed by Astra Ab filed Critical Astra Ab

1995-11-27 Publication of IL95979A publication Critical patent/IL95979A/en

Links

229930192649 bafilomycin Natural products 0.000 title claims description 16
239000008194 pharmaceutical composition Substances 0.000 title claims description 9
150000001875 compounds Chemical class 0.000 claims description 44
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
210000000988 bone and bone Anatomy 0.000 claims description 21
201000010099 disease Diseases 0.000 claims description 21
208000001132 Osteoporosis Diseases 0.000 claims description 16
XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 claims description 15
208000006386 Bone Resorption Diseases 0.000 claims description 14
230000024279 bone resorption Effects 0.000 claims description 14
206010065687 Bone loss Diseases 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
239000007943 implant Substances 0.000 claims description 8
239000000825 pharmaceutical preparation Substances 0.000 claims description 8
210000004881 tumor cell Anatomy 0.000 claims description 7
208000010191 Osteitis Deformans Diseases 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 6
201000011510 cancer Diseases 0.000 claims description 6
206010028980 Neoplasm Diseases 0.000 claims description 5
230000003211 malignant effect Effects 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
208000027067 Paget disease of bone Diseases 0.000 claims description 4
239000013543 active substance Substances 0.000 claims description 4
208000016738 bone Paget disease Diseases 0.000 claims description 4
208000010392 Bone Fractures Diseases 0.000 claims description 3
230000035876 healing Effects 0.000 claims description 3
208000020084 Bone disease Diseases 0.000 claims description 2
239000000203 mixture Substances 0.000 claims 11
206010020707 Hyperparathyroidism primary Diseases 0.000 claims 2
201000000981 Primary Hyperparathyroidism Diseases 0.000 claims 2
208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 2
ZKOTUWJMGBWBEO-YXTSRGFTSA-N (3e,5e,7r,8s,9s,11e,13e,15s,16r)-16-[(e,2s,3r,4s,8s,9r)-3,9-dihydroxy-4,8,10-trimethyl-5-oxoundec-6-en-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one Chemical compound CO[C@H]1\C=C\C=C(C)\C[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C=C(OC)/C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)C(=O)\C=C\[C@H](C)[C@H](O)C(C)C ZKOTUWJMGBWBEO-YXTSRGFTSA-N 0.000 claims 1
ZKOTUWJMGBWBEO-NTKKXMPNSA-N bafilomycin D Natural products CO[C@H]1C=CC=C(C)C[C@H](C)[C@H](O)[C@H](C)C=C(C)C=C(OC)C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)C(=O)C=C[C@H](C)[C@H](O)C(C)C ZKOTUWJMGBWBEO-NTKKXMPNSA-N 0.000 claims 1
239000004615 ingredient Substances 0.000 claims 1
102000003982 Parathyroid hormone Human genes 0.000 description 12
108090000445 Parathyroid hormone Proteins 0.000 description 12
239000000199 parathyroid hormone Substances 0.000 description 12
229960001319 parathyroid hormone Drugs 0.000 description 12
208000037147 Hypercalcaemia Diseases 0.000 description 7
230000000148 hypercalcaemia Effects 0.000 description 7
208000030915 hypercalcemia disease Diseases 0.000 description 7
230000000694 effects Effects 0.000 description 6
206010017076 Fracture Diseases 0.000 description 5
201000002980 Hyperparathyroidism Diseases 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
238000000034 method Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
102000055006 Calcitonin Human genes 0.000 description 3
108060001064 Calcitonin Proteins 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
229960004015 calcitonin Drugs 0.000 description 3
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000011164 ossification Effects 0.000 description 3
230000001599 osteoclastic effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
102000004125 Interleukin-1alpha Human genes 0.000 description 2
108010082786 Interleukin-1alpha Proteins 0.000 description 2
208000027868 Paget disease Diseases 0.000 description 2
XDHNQDDQEHDUTM-JQWOJBOSSA-N bafilomycin A1 Chemical compound CO[C@H]1\C=C\C=C(C)\C[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C=C(OC)\C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C1 XDHNQDDQEHDUTM-JQWOJBOSSA-N 0.000 description 2
XDHNQDDQEHDUTM-ZGOPVUMHSA-N bafilomycin A1 Natural products CO[C@H]1C=CC=C(C)C[C@H](C)[C@H](O)[C@H](C)C=C(C)C=C(OC)C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C1 XDHNQDDQEHDUTM-ZGOPVUMHSA-N 0.000 description 2
229940011871 estrogen Drugs 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
210000002411 hand bone Anatomy 0.000 description 2
GEZBIZMDLMTFDB-KJKHOEIASA-N hygrolidin Chemical class CO[C@H]1\C=C\C=C(C)\C[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C=C(C)\C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C)[C@H](C)[C@H](OC(=O)\C=C\C(O)=O)C1 GEZBIZMDLMTFDB-KJKHOEIASA-N 0.000 description 2
208000027202 mammary Paget disease Diseases 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
210000000963 osteoblast Anatomy 0.000 description 2
210000002997 osteoclast Anatomy 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
206010006002 Bone pain Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
SPAGSIKUEDKARP-UHFFFAOYSA-N Defumarylhygrolidin Natural products CCC1OC(O)(CC(O)C1C)C(C)C(O)C(C)C2OC(=O)C(=CC(=CC(C)C(O)C(C)CC(=CC=CC2OC)C)C)C SPAGSIKUEDKARP-UHFFFAOYSA-N 0.000 description 1
241000534671 Hiodon Species 0.000 description 1
206010020100 Hip fracture Diseases 0.000 description 1
UGIOXKVQFJIRMZ-UHFFFAOYSA-N Hygrolidin Natural products C1C(OC(=O)C=CC(O)=O)C(C)C(CC)OC1(O)C(C)C(O)C(C)C1C(OC)C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(C)C(=O)O1 UGIOXKVQFJIRMZ-UHFFFAOYSA-N 0.000 description 1
NYSJCTVMECTFDC-UHFFFAOYSA-N Hygrolidin amide Natural products CCC1OC(O)(CC(OC(=O)C=CC(N)=O)C1C)C(C)C(O)C(C)C1OC(=O)C(C)=CC(C)=CC(C)C(O)C(C)CC(C)=CC=CC1OC NYSJCTVMECTFDC-UHFFFAOYSA-N 0.000 description 1
HBTGJJXCZRLXJW-ZORNFIJTSA-N Oxohygrolidin Natural products CCC(O)C(C)C=CC(=O)C(C)C(O)C(C)C1OC(=O)C(=C/C(=C/C(C)C(O)C(C)CC(=CC=CC1OC)C)/C)C HBTGJJXCZRLXJW-ZORNFIJTSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
NYSJCTVMECTFDC-AEZCHWMWSA-N [(2R,4R,5S,6R)-6-ethyl-2-hydroxy-2-[(2S,3R,4S)-3-hydroxy-4-[(2R,3S,4E,6E,9S,10S,11R,12E,14E)-10-hydroxy-3-methoxy-7,9,11,13,15-pentamethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-5-methyloxan-4-yl] (E)-4-amino-4-oxobut-2-enoate Chemical compound CC[C@H]1O[C@](O)(C[C@@H](OC(=O)\C=C\C(N)=O)[C@H]1C)[C@@H](C)[C@H](O)[C@H](C)[C@H]1OC(=O)\C(C)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC NYSJCTVMECTFDC-AEZCHWMWSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
230000010072 bone remodeling Effects 0.000 description 1
230000003913 calcium metabolism Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000002281 colonystimulating effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
150000001993 dienes Chemical class 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
230000001009 osteoporotic effect Effects 0.000 description 1
HBTGJJXCZRLXJW-YXHYICRGSA-N oxohygrolidin Chemical compound CCC(O)C(C)\C=C/C(=O)C(C)C(O)C(C)C1OC(=O)\C(C)=C\C(\C)=C\C(C)C(O)C(C)C\C(C)=C/C=C/C1OC HBTGJJXCZRLXJW-YXHYICRGSA-N 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
206010041569 spinal fracture Diseases 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IL9597990A 1989-10-24 1990-10-12 Pharmaceutical preparations containing phylomycins IL95979A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8903529A SE8903529D0 (sv)	1989-10-24	1989-10-24	Medical use

Publications (1)

Publication Number	Publication Date
IL95979A true IL95979A (en)	1995-11-27

Family

ID=20377263

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9597990A IL95979A (en)	1989-10-24	1990-10-12	Pharmaceutical preparations containing phylomycins

Country Status (10)

Country	Link
US (1)	US5354773A (ja)
EP (1)	EP0497845A1 (ja)
JP (1)	JPH05501409A (ja)
CA (1)	CA2071914A1 (ja)
HU (1)	HUT60919A (ja)
IE (1)	IE903793A1 (ja)
IL (1)	IL95979A (ja)
NZ (1)	NZ235610A (ja)
SE (1)	SE8903529D0 (ja)
WO (1)	WO1991006296A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5306716A (en) *	1992-03-20	1994-04-26	Merck & Co., Inc.	Methods of achieving antileukemia activity using 16-membered-macrolide-type compounds
US5324720A (en) *	1992-03-20	1994-06-28	Merck & Co., Inc.	Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
EP0639644A1 (de) *	1993-08-16	1995-02-22	Ciba-Geigy Ag	Neue Makrolide und ihre Verwendung
DE19828068C2 (de) *	1998-06-24	2003-12-18	Peter Dietsch	Mittel zur spezifischen Hemmung osteoklastärer Knochenresorption
WO2000028982A2 (en)	1998-11-19	2000-05-25	The Board Of Trustees For The University Of Arkansas	Increasing bone strength with selected bisphosphonates
ES2165747A1 (es) *	1999-01-20	2002-03-16	Smithkline Beecham Sa	Depsipeptidos como inhibidores de resorcion de hueso.
DE10040052A1 (de) *	2000-08-11	2002-03-07	Univ Eberhard Karls	Verwendung von Protonenpumpen-Hemmern zur Behandlung von Entzündungen, insbesondere von Erkrankungen des Bewegungsapparates
JP2005514972A (ja) *	2001-11-29	2005-05-26	ジェジュテク，キャシー	吸収が調節される骨インプラント
US7541330B2 (en) *	2004-06-15	2009-06-02	Kosan Biosciences Incorporated	Conjugates with reduced adverse systemic effects
CN104817547B (zh) *	2015-03-17	2016-02-24	农业部环境保护科研监测所	新型巴弗洛霉素、其提取微生物和提取方法
EP4263516A1 (en) *	2020-12-16	2023-10-25	The Regents of The University of Michigan	Inhibitors of nef downmodulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3310533A1 (de) *	1983-03-23	1984-09-27	Bayer Ag, 5090 Leverkusen	Organisch-chemische verbindungen und verfahren zu ihrer herstellung

1989
- 1989-10-24 SE SE8903529A patent/SE8903529D0/xx unknown
1990
- 1990-10-09 NZ NZ235610A patent/NZ235610A/xx unknown
- 1990-10-12 IL IL9597990A patent/IL95979A/en not_active IP Right Cessation
- 1990-10-22 US US07/849,020 patent/US5354773A/en not_active Expired - Fee Related
- 1990-10-22 HU HU921364A patent/HUT60919A/hu unknown
- 1990-10-22 JP JP2514919A patent/JPH05501409A/ja active Pending
- 1990-10-22 EP EP90916159A patent/EP0497845A1/en not_active Ceased
- 1990-10-22 CA CA002071914A patent/CA2071914A1/en not_active Abandoned
- 1990-10-22 WO PCT/SE1990/000684 patent/WO1991006296A1/en not_active Ceased
- 1990-10-23 IE IE379390A patent/IE903793A1/en unknown

Also Published As

Publication number	Publication date
SE8903529D0 (sv)	1989-10-24
EP0497845A1 (en)	1992-08-12
US5354773A (en)	1994-10-11
WO1991006296A1 (en)	1991-05-16
HUT60919A (en)	1992-11-30
AU641445B2 (en)	1993-09-23
IE903793A1 (en)	1991-04-24
JPH05501409A (ja)	1993-03-18
AU6622990A (en)	1991-05-31
NZ235610A (en)	1993-09-27
HU9201364D0 (en)	1992-07-28
CA2071914A1 (en)	1991-04-25

Legal Events

Date	Code	Title	Description
1996-05-14	FF	Patent granted
1997-08-14	RH	Patent void

Publication	Publication Date	Title
JP3657516B2 (ja)	2005-06-08	感染症の治療および予防処置のための有機リン化合物の使用
US4916241A (en)	1990-04-10	Inhibition of bone loss by 4-substituted-5-hydroxy-2(5H)-furanones
JPH02501929A (ja)	1990-06-28	医学的使用
US5354773A (en)	1994-10-11	Use of bafilomycine and derivatives to treat bone diseases
WO2001052829A2 (en)	2001-07-26	Statin-type bone growth stimulators
KR100424503B1 (ko)	2004-06-04	암전이억제제
BG104630A (en)	2001-04-30	Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US4578376A (en)	1986-03-25	Pharmaceutical compositions for the treatment of osteopathias
HUT76338A (en)	1997-08-28	8alfa-equilin isomer process for its production and pharmaceutical composition containing it
WO1989003830A1 (en)	1989-05-05	2-pyridinylmethyl (sulfinyl or thio)benzimidazoles for treatment of diseases related to bone loss
KR20040095346A (ko)	2004-11-12	신생 골의 형성을 유도하기 위한 탄소-2-개질된 19-노르-비타민 ｄ 유사체의 용도
KR100624238B1 (ko)	2006-09-19	알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물
AU641445C (en)	1994-09-15	Bafilomycine macrolides for treatment of bone affecting diseases
KR101308144B1 (ko)	2013-09-12	아젤라신 ｄ를 유효성분으로 함유하는 골질환 예방 또는 치료용 약학적 조성물
JPH02502188A (ja)	1990-07-19	新規な治療的使用
AU2010232694A1 (en)	2011-10-27	Method of treating osteoporosis
JPH07215849A (ja)	1995-08-15	抗骨粗鬆症剤
KR20000019869A (ko)	2000-04-15	홍화자 추출물을 포함하는 경조직 재생촉진제 조성물
EP1328277B1 (en)	2007-02-14	Bisphosphonic compounds for strengthening of cortical bone
US5026725A (en)	1991-06-25	Inhibition of bone loss by 4-substituted-5-hydroxy-2(5H)-furanones
US20060173069A1 (en)	2006-08-03	Therapeutic agent for hyperpotassemia and bone disease
EP0293146A1 (en)	1988-11-30	Benzofuro [3,2-c] quinoline compounds
KR102531782B1 (ko)	2023-05-12	루토나린을 포함하는 골질환 예방 또는 치료용 조성물
WO2024154990A1 (ko)	2024-07-25	가는새빨간검둥이 추출물을 포함하는 골 질환의 예방 또는 치료용 약학적 조성물
KR20030013177A (ko)	2003-02-14	퀴에르시트린을 유효성분으로 하는 약학적 조성물